Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $1.98, but opened at $2.05. Lexicon Pharmaceuticals shares last traded at $2.06, with a volume of 905,344 shares trading hands.
Lexicon Pharmaceuticals Price Performance
The firm has a fifty day moving average of $1.40 and a two-hundred day moving average of $1.43. The stock has a market capitalization of $506.98 million, a P/E ratio of -2.78 and a beta of 1.23. The company has a debt-to-equity ratio of 0.71, a current ratio of 6.92 and a quick ratio of 6.91.
Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.01. The firm had revenue of $0.16 million for the quarter, compared to the consensus estimate of $1.49 million. Lexicon Pharmaceuticals had a negative net margin of 29,728.25% and a negative return on equity of 118.90%. On average, analysts predict that Lexicon Pharmaceuticals, Inc. will post -0.81 EPS for the current year.
Insider Activity
In other news, CEO Lonnel Coats bought 90,000 shares of the stock in a transaction on Thursday, November 16th. The stock was bought at an average cost of $1.05 per share, for a total transaction of $94,500.00. Following the completion of the purchase, the chief executive officer now directly owns 914,359 shares in the company, valued at $960,076.95. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 6.80% of the company's stock.
Institutional Trading of Lexicon Pharmaceuticals
A number of institutional investors have recently bought and sold shares of the stock. Artal Group S.A. lifted its position in Lexicon Pharmaceuticals by 30.9% during the 2nd quarter. Artal Group S.A. now owns 117,553,284 shares of the biopharmaceutical company's stock worth $269,197,000 after acquiring an additional 27,775,050 shares during the period. BVF Inc. IL lifted its holdings in shares of Lexicon Pharmaceuticals by 23.8% during the second quarter. BVF Inc. IL now owns 19,995,332 shares of the biopharmaceutical company's stock worth $45,789,000 after purchasing an additional 3,846,153 shares during the period. BlackRock Inc. boosted its position in Lexicon Pharmaceuticals by 12.8% in the second quarter. BlackRock Inc. now owns 6,379,186 shares of the biopharmaceutical company's stock valued at $14,608,000 after buying an additional 722,259 shares during the last quarter. Vanguard Group Inc. increased its holdings in Lexicon Pharmaceuticals by 34.0% in the 3rd quarter. Vanguard Group Inc. now owns 5,256,288 shares of the biopharmaceutical company's stock worth $12,614,000 after buying an additional 1,334,318 shares during the period. Finally, JPMorgan Chase & Co. raised its position in Lexicon Pharmaceuticals by 0.9% during the 1st quarter. JPMorgan Chase & Co. now owns 3,305,991 shares of the biopharmaceutical company's stock worth $8,034,000 after buying an additional 29,193 shares during the last quarter.
About Lexicon Pharmaceuticals
(
Get Free Report)
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Lexicon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexicon Pharmaceuticals wasn't on the list.
While Lexicon Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
